logo-loader
AIM:AMYT

Amryt Pharma PLC

 Receive alerts
Market:
AIM
Market Cap:
£185.59 m
Price
117.67 GBX
Change
1.00%
52 weeks high
143.00
52 weeks low
69.90
07.56

Director Interviews

In brief

Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Amryt Pharma: US deal set to transform the orphan drug company
Amryt Pharma PLC -

Snapshot

  • A revenue-generating orphan drugs company
  • Completed a transformational deal
  • Expected to be a high growth business  
Open Deep dive

Latest news

Amryt Pharma: US Food & Drug Administration gives phase III drug fast-track...

2 weeks, 2 days ago

Amryt Pharma concludes transformational Aegerion deal

3 weeks, 1 day ago

Amryt soars as US bankruptcy court clears way for Aegerion acquisition

on 11/9/19

Amryt Pharma provides detail of Aegerion deal

on 27/8/19

Open Orphan starts trading on AIM

on 28/6/19

Venn Life Sciences launches £4.5mln share placing to fund life after reverse...

on 11/6/19

Amryt Phama to take control of Lojuxta through merger with US firm Aegerion

on 21/5/19

Open Orphan set to join AIM as it agrees reverse takeover of Venn Life Sciences

on 10/5/19

Interviews

Amryt Pharma PLC - Investor Update: Amryt Pharma's AP101 given fast-track status by US regulator Mining Investor Update: Amryt Pharma's AP101 given fast-track status by US regulator
2 weeks, 2 days ago
Amryt Pharma PLC - Amryt Pharma completes on 'transformational' acquisition and US$60mln fundraise Health Amryt Pharma completes on 'transformational' acquisition and US$60mln fundraise
3 weeks, 1 day ago
Open Orphan - Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition Health Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition
on 13/9/19
1561637215_CATHAL_JUNE_27.jpg Health Shareholders approve Venn Life Sciences PLC / Open Orphan merger
on 27/6/19
View all